SUBSCRIBE
SUBSCRIBE
News   Policy

Sanofi-Aventis (France)'s Multaq to get U.S. Panel Review in March

December 1, 2008 | 
1 min read
PARIS, Nov 27 (Reuters) - Sanofi-Aventis' experimental heart drug Multaq will be reviewed by an independent expert panel in the United States next March, marking a delay in a priority review by the health regulator.
Regulatory Europe
Sanofi (France)
MORE ON THIS TOPIC
FDA Commissioner Dr. Marty Makary delivers remarks after President Donald Trump made an announcement on drug pricing, Tuesday, September 30, 2025, in the Oval Office. (Official White House Photo by Joyce N. Boghosian)
Government
Signs of Frustration Build Between Kennedy and FDA Commissioner Makary
November 17, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers
November 12, 2025
 · 
1 min read
 · 
Heather McKenzie
Silver Spring, MD, USA 11/10/2020: Exterior view of the headquarters of US Food and Drug Administration (FDA). This federal agency approves medications, vaccines and food additives for human use.
FDA
FDA Stalwart Pazdur Named Tidmarsh’s Replacement as CDER Director
November 11, 2025
 · 
1 min read
 · 
Heather McKenzie
factory of the pharmaceutical industry. pills on the conveyor
Manufacturing
Drugmakers Push FDA To Extend Support to Existing Facilities
November 11, 2025
 · 
4 min read
 · 
Nick Paul Taylor